CCO Infectious Disease Podcast

In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:Barriers to screening HDV screening based on patient risk factors Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)Reflex testing Availability of commercial testingMonitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNALimitations to evaluating advanced fibrosis in patients with HDVData on novel HDV therapies (eg, bulevirtide and lonafarnib)Extending HDV therapy (eg, peginterferon) based on treatment responseStopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapyFaculty:Maria Buti, MDProfessor of MedicineHospital Universitario Vall d’HebronBarcelona, SpainRichard H. Davis, PA-CSenior PAGastroenterologyUniversity of FloridaUF HealthGainesville, FloridaLink to full program: http://bit.ly/3yp1Lxf

In this episode, Latesha Elopre, MD, MSPH, discusses key considerations to barriers to PrEP uptake, including:Addressing disparities among racial and ethnic minority populationsUnderstanding the concept of intersectionality Tackling multiple levels of intersectionalityIndividual (eg, self-stigma, mental health)Network (eg, access to PrEP services)Community (eg, racism, stigma, poverty)Social and structural (eg, laws/policies)Epidemic (eg, population level of viremia)Presenter: Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZjSFhgFollow along with the slides:https://bit.ly/3YmeRWy

In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:Efficacy dataInitiation strategiesVirologic failure dataSafety informationPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:http://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Darcey Wooten, MD, discusses updated guidance and rationale for monitoring for new HIV infections in people receiving long-acting PrEP, including:Testing both Ag/Ab and HIV-1 RNASteps to take when a person receiving long-acting PrEP develops a new HIV infectionPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:https://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Nancy Reau, MD, and Lydia Tang, MBChB, discuss how to increase linkage to care rates for persons with hepatitis D virus, including:Updates on currently low rates of linkage to careBarriers preventing patients with HBV/HDV coinfection from engaging in careInterventions to increase retention in care for patients with HDV Faculty: Nancy Reau, MDProfessor of MedicineChief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLydia Tang, MBChB Assistant ProfessorDepartment of Infectious DiseasesUniversity of Maryland School of MedicineInstitute of Human VirologyBaltimore, MarylandLink to full program: https://bit.ly/41oYawrFollow along with the slides at: https://bit.ly/3XW6m4g

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)Optimizing the use of the Antiretroviral Pregnancy RegistryAddressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)Faculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public Health University of California, San DiegoSan Diego, CaliforniaWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious Diseases Department of Medicine  Perelman School of Medicine at the University of Pennsylvania Philadelphia, PennsylvaniaLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz

In this episode, Coleman I. Smith, MD, and Lydia Tang, MBChB, discuss how to screen for hepatitis delta virus (HDV), including:Algorithm for evaluation of HDVDiagnosis of different stages of HDV infection Strategies to increase HDV testing rates Faculty:Coleman I. Smith, MDProfessor of MedicineHepatologistGeorgetown Transplant InstituteGeorgetown UniversityWashington, DCLydia Tang, MBChB Assistant ProfessorDepartment of Infectious DiseasesUniversity of Maryland School of MedicineInstitute of Human VirologyBaltimore, MarylandLink to full program:http://bit.ly/41oYawrFollow along with the slides at: http://bit.ly/3XW6m4g

In this episode, Canadian HIV experts share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.Specifically, the faculty discuss treatment strategies for patients with a history of NRTI resistance based on findings from the 2SD and NADIA trials; the latest data informing the use of 2-drug oral and injectable treatment regimens; prevention approaches for HIV and other sexually transmitted infections based on findings from the DoxyPEP, HPTN 083, and HPTN 084 trials; and other emerging innovations in HIV care.Presenters:Jean-Guy Baril, MDAssociate ProfessorFamily MedicineUniversité de MontrealMontreal, Quebec, CanadaAlexander Wong MD, FRCPCAssociate ProfessorDepartment of MedicineUniversity of SaskatchewanRegina, Saskatchewan, CanadaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E

 In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.  Presenters:Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of Melbourne  Consultant Infectious Diseases PhysicianAlfred Hospital and Royal Melbourne Hospital  Melbourne, AustraliaDon Smith, MDConjoint ProfessorSchool of Population MedicineUniversity of New South WalesSenior Staff SpecialistAlbion CentreSouth Eastern Sydney Local Health NetworkSydney, AustraliaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E  

In this episode, 2 HIV experts from Latin America share their thoughts on the current status of HIV prevention strategies in the region, including recent successes and ongoing challenges. Specifically, the faculty discuss:Barriers that limit PrEP availability in many regions of Latin America despite the high need among vulnerable and at-risk groupsSuccessful expansion of PrEP access in BrazilKey findings from the prospective ImPrEP study evaluating implementation of same-day oral PrEP among men who have sex with men and transgender women in Brazil, Mexico, and PeruWhat long-acting PrEP could mean for at-risk groups in Latin America when it becomes availableImportant considerations for PrEP among TGW Presenters:Claudia P. Cortes MDAssociate ProfessorInfectious DiseasesUniversidad de ChileSantiago, ChileBeatriz Grinsztejn MD, PhD Diretora, STD/HIV Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro ChagasOswaldo Cruz Foundation Rio de Janeiro, BrazilContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E